These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. How to interpret an overview: a meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Easterbrook PJ Genitourin Med; 1997 Apr; 73(2):139-43. PubMed ID: 9215100 [No Abstract] [Full Text] [Related]
4. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98. Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E; N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138 [TBL] [Abstract][Full Text] [Related]
5. [Effect of dapsone on survival in HIV infected patients: a meta- analysis of finished trials]. Saillourglénisson F; Chêne G; Salmi LR; Hafner R; Salamon R Rev Epidemiol Sante Publique; 2000 Jan; 48(1):17-30. PubMed ID: 10740082 [TBL] [Abstract][Full Text] [Related]
6. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV. Podzamczer D; Salazar A; Jiménez J; Consiglio E; Santín M; Casanova A; Rufí G; Gudiol F Ann Intern Med; 1995 May; 122(10):755-61. PubMed ID: 7717598 [TBL] [Abstract][Full Text] [Related]
7. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. El-Sadr WM; Murphy RL; Yurik TM; Luskin-Hawk R; Cheung TW; Balfour HH; Eng R; Hooton TM; Kerkering TM; Schutz M; van der Horst C; Hafner R N Engl J Med; 1998 Dec; 339(26):1889-95. PubMed ID: 9862944 [TBL] [Abstract][Full Text] [Related]
8. Pneumocystis carinii pneumonia following discontinuation of primary prophylaxis despite highly active antiretroviral therapy. Mammen-Tobin A; Monteiro EF Int J STD AIDS; 2000 Jan; 11(1):64-5. PubMed ID: 10667904 [No Abstract] [Full Text] [Related]
9. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Green H; Paul M; Vidal L; Leibovici L Mayo Clin Proc; 2007 Sep; 82(9):1052-9. PubMed ID: 17803871 [TBL] [Abstract][Full Text] [Related]
11. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Ioannidis JP; Cappelleri JC; Skolnik PR; Lau J; Sacks HS Arch Intern Med; 1996 Jan; 156(2):177-88. PubMed ID: 8546551 [TBL] [Abstract][Full Text] [Related]
12. Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. Antinori A; Murri R; Ammassari A; De Luca A; Linzalone A; Cingolani A; Damiano F; Maiuro G; Vecchiet J; Scoppettuolo G AIDS; 1995 Dec; 9(12):1343-50. PubMed ID: 8605054 [TBL] [Abstract][Full Text] [Related]
13. Intention-to-treat vs. on-treatment analyses of clinical trial data: experience from a study of pyrimethamine in the primary prophylaxis of toxoplasmosis in HIV-infected patients. ANRS 005/ACTG 154 Trial Group. Chêne G; Morlat P; Leport C; Hafner R; Dequae L; Charreau I; Aboulker JP; Luft B; Aubertin J; Vildé JL; Salamon R Control Clin Trials; 1998 Jun; 19(3):233-48. PubMed ID: 9620807 [TBL] [Abstract][Full Text] [Related]
14. Discontinuing prophylaxis against Pneumocystis carinii pneumonia. Bender MA; Sax PE N Engl J Med; 2001 May; 344(21):1639; author reply 1640-1. PubMed ID: 11374364 [No Abstract] [Full Text] [Related]
15. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. Ledergerber B; Mocroft A; Reiss P; Furrer H; Kirk O; Bickel M; Uberti-Foppa C; Pradier C; D'Arminio Monforte A; Schneider MM; Lundgren JD; N Engl J Med; 2001 Jan; 344(3):168-74. PubMed ID: 11188837 [TBL] [Abstract][Full Text] [Related]